Cargando…
Dupilumab for the treatment of pembrolizumab‐induced bullous pemphigoid: A case report
Autores principales: | Pop, Samantha R., Strock, Daniel, Smith, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539473/ https://www.ncbi.nlm.nih.gov/pubmed/35669992 http://dx.doi.org/10.1111/dth.15623 |
Ejemplares similares
-
Pembrolizumab-induced bullous pemphigoid
por: Sun, Christina W., et al.
Publicado: (2019) -
Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid
por: Manzo Margiotta, Flavia, et al.
Publicado: (2023) -
The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab
por: Savoldy, Michelle A, et al.
Publicado: (2022) -
Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid
por: Seyed Jafari, S. Morteza, et al.
Publicado: (2021) -
Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid
por: Zhang, Xiaoyan, et al.
Publicado: (2021)